ホームページ GPCR & G Protein FPR

FPR

亜型選択性的な製品

FPR製品

  • All (6)
  • FPR拮抗剤(2)
  • FPR作動薬(2)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S9818 WRW4 WRW4 is a specific formyl peptide receptor-like 1 (FPRL1) antagonist that inhibits WKYMVm binding to FPRL1 with IC50 of 0.23 μM. WRW4 is a selective antagonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX).
Int J Biol Sci, 2024, 20(12):4941-4956
Chin Med, 2024, 19(1):104
E4628New BMS-986235 BMS-986235 (LAR-1219) is a selective, orally active and potent agonist of formyl peptide receptor 2 (FPR2), with EC50 values of 0.41 nM and 3.4 nM for hFPR2 and mFPR2, respectively. BMS-986235 therapy shows promising improvements in cardiac structure and function in a mouse model of heart failure, highlighting its potential for preventing the progression of heart failure.
S0547 HCH6-1 HCH6-1 is a selective competitive antagonist of formyl peptide receptor 1 (FPR1) and has protective effects against acute lung injury (ALI). HCH6-1 may have potential as a new therapeutic agent for treating FPR1-involved inflammatory lung diseases.
E1313 N-Formyl-Met-Leu-Phe (fMLP) N-Formyl-Met-Leu-Phe (fMLP) is an endogenous chemotactic peptide and agonist for the formyl peptide receptor 1 (FPR1) with Ki of 38 nM. It stimulates aggregation of leukocytes.
E4628New BMS-986235 BMS-986235 (LAR-1219) is a selective, orally active and potent agonist of formyl peptide receptor 2 (FPR2), with EC50 values of 0.41 nM and 3.4 nM for hFPR2 and mFPR2, respectively. BMS-986235 therapy shows promising improvements in cardiac structure and function in a mouse model of heart failure, highlighting its potential for preventing the progression of heart failure.
E1313 N-Formyl-Met-Leu-Phe (fMLP) N-Formyl-Met-Leu-Phe (fMLP) is an endogenous chemotactic peptide and agonist for the formyl peptide receptor 1 (FPR1) with Ki of 38 nM. It stimulates aggregation of leukocytes.
S9818 WRW4 WRW4 is a specific formyl peptide receptor-like 1 (FPRL1) antagonist that inhibits WKYMVm binding to FPRL1 with IC50 of 0.23 μM. WRW4 is a selective antagonist of formyl peptide receptor type 2 (FPR2)/Lipoxin A4 receptor (ALX).
Int J Biol Sci, 2024, 20(12):4941-4956
Chin Med, 2024, 19(1):104
S0547 HCH6-1 HCH6-1 is a selective competitive antagonist of formyl peptide receptor 1 (FPR1) and has protective effects against acute lung injury (ALI). HCH6-1 may have potential as a new therapeutic agent for treating FPR1-involved inflammatory lung diseases.
E4628New BMS-986235 BMS-986235 (LAR-1219) is a selective, orally active and potent agonist of formyl peptide receptor 2 (FPR2), with EC50 values of 0.41 nM and 3.4 nM for hFPR2 and mFPR2, respectively. BMS-986235 therapy shows promising improvements in cardiac structure and function in a mouse model of heart failure, highlighting its potential for preventing the progression of heart failure.
E1313 N-Formyl-Met-Leu-Phe (fMLP) N-Formyl-Met-Leu-Phe (fMLP) is an endogenous chemotactic peptide and agonist for the formyl peptide receptor 1 (FPR1) with Ki of 38 nM. It stimulates aggregation of leukocytes.
E4628New BMS-986235 BMS-986235 (LAR-1219) is a selective, orally active and potent agonist of formyl peptide receptor 2 (FPR2), with EC50 values of 0.41 nM and 3.4 nM for hFPR2 and mFPR2, respectively. BMS-986235 therapy shows promising improvements in cardiac structure and function in a mouse model of heart failure, highlighting its potential for preventing the progression of heart failure.
E4628New BMS-986235 BMS-986235 (LAR-1219) is a selective, orally active and potent agonist of formyl peptide receptor 2 (FPR2), with EC50 values of 0.41 nM and 3.4 nM for hFPR2 and mFPR2, respectively. BMS-986235 therapy shows promising improvements in cardiac structure and function in a mouse model of heart failure, highlighting its potential for preventing the progression of heart failure.

FPR阻害剤の選択性比較

Tags: FPR inhibitor|FPR agonist|FPR activator|FPR inducer|FPR antagonist|FPR signaling pathway|FPR assay kit